Alimera Sciences, Inc. (ALIM)’s President and CFO Richard Eiswirth Sold 14,494 Shares; Heska (HSKA) Has 1.26 Sentiment

Heska Corporation develops, manufactures, and markets advanced veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company has market cap of $579.79 million. It operates through two divisions, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. It has a 41.97 P/E ratio. The Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and IV pumps.

Company insider, Richard Eiswirth, President and CFO of Alimera Sciences Inc unloaded a total of 14,494 shares of the firm, estimated based on $1.2 a share. At present, Richard Eiswirth holds a total of 91,380 shares or 0.13% of the Company’s total market cap.

Analysts await Alimera Sciences, Inc. (NASDAQ:ALIM) to report earnings on March, 7. They expect $-0.03 EPS, up 70.00% or $0.07 from last year’s $-0.1 per share. After $-0.04 actual EPS reported by Alimera Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Among 3 analysts covering Alimera Sciences (NASDAQ:ALIM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alimera Sciences has $10 highest and $300 lowest target. $4.67’s average target is 276.61% above currents $1.24 stock price. Alimera Sciences had 13 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Friday, October 27 with “Buy”. The stock of Alimera Sciences, Inc. (NASDAQ:ALIM) earned “Outperform” rating by Cowen & Co on Friday, September 16. The stock has “Buy” rating by Cowen & Co on Tuesday, July 11. The rating was maintained by H.C. Wainwright on Wednesday, July 26 with “Buy”. H.C. Wainwright maintained Alimera Sciences, Inc. (NASDAQ:ALIM) rating on Tuesday, July 11. H.C. Wainwright has “Buy” rating and $500 target. The firm has “Buy” rating given on Tuesday, July 25 by Cowen & Co. The firm has “Buy” rating given on Friday, August 4 by H.C. Wainwright. Cowen & Co maintained Alimera Sciences, Inc. (NASDAQ:ALIM) rating on Thursday, August 3. Cowen & Co has “Buy” rating and $300 target. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, January 19. Cantor Fitzgerald maintained the shares of ALIM in report on Wednesday, August 12 with “Buy” rating.

The stock 0.40% or $0 during the last trading session, reaching $1.24. It is up 0.67% since January 19, 2017 and is uptrending. It has underperformed by 16.03% the S&P500.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $85.74 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Investors sentiment increased to 1.64 in 2017 Q3. Its up 0.57, from 1.07 in 2017Q2. It is positive, as 4 investors sold Alimera Sciences, Inc. shares while 7 reduced holdings. 8 funds opened positions while 10 raised stakes. 28.40 million shares or 11.41% more from 25.49 million shares in 2017Q2 were reported. Renaissance Technologies Lc, New York-based fund reported 468,005 shares. Jpmorgan Chase & has invested 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Orbimed Advsrs Limited Liability Company invested 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). The New York-based Tower Rech Capital Limited Liability Company (Trc) has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Morgan Stanley reported 400 shares. Moreover, Vanguard Group has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 2.07 million shares. Goldman Sachs Grp has 118,859 shares. 974,318 are held by Acuta Cap Prns Ltd Company. Venbio Select Advisor Ltd Co reported 0.65% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Jw Asset Mngmt Limited Liability Co invested in 0.96% or 966,000 shares. Geode Cap Mngmt Ltd Liability Corp reported 156,604 shares. Deutsche Fincl Bank Ag has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM). Palo Alto Investors Ltd Llc accumulated 3.01M shares. 6.26M were accumulated by Armistice Limited Liability Corporation. Northern Trust Corp holds 102,791 shares or 0% of its portfolio.

Analysts await Heska Corporation (NASDAQ:HSKA) to report earnings on February, 27. They expect $0.60 EPS, up 30.43% or $0.14 from last year’s $0.46 per share. HSKA’s profit will be $4.35M for 33.35 P/E if the $0.60 EPS becomes a reality. After $0.40 actual EPS reported by Heska Corporation for the previous quarter, Wall Street now forecasts 50.00% EPS growth.

Ratings analysis reveals 50% of Heska Corp’s analysts are positive. Out of 2 Wall Street analysts rating Heska Corp, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. HSKA was included in 2 notes of analysts from November 29, 2016. The firm has “Neutral” rating by CL King given on Thursday, January 26. The firm earned “Buy” rating on Tuesday, November 29 by Benchmark.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $348,184 activity.

Grace & White Inc Ny holds 1.49% of its portfolio in Heska Corporation for 81,210 shares. Summit Creek Advisors Llc owns 56,638 shares or 0.98% of their US portfolio. Moreover, Timpani Capital Management Llc has 0.76% invested in the company for 23,639 shares. The California-based Globeflex Capital L P has invested 0.62% in the stock. Park West Asset Management Llc, a California-based fund reported 88,390 shares.